Abstract This paper examines Health Technology Assessment (HTA) as a rigorous and transparent process that supports evidence-based decision-making in healthcare systems. HTA evaluates health technologies, including medicines, medical devices, procedures, and interventions, by considering their clinical effectiveness, safety, cost-effectiveness, ethical implications, legal dimensions, and social impact. The paper highlights the role of HTA in guiding decisions related to reimbursement, acquisition, price negotiation, and the integration of innovations into healthcare practice. It also emphasizes the importance of different decision-making levels: clinicians at the micro level, healthcare institutions at the meso level, and public authorities and payers at the macro level. Through examples of international HTA structures such as NICE, CADTH, FDA, AHRQ, and IQWiG, the paper shows how countries organize assessment mechanisms according to their healthcare priorities and institutional capacities. Particular attention is given to Morocco, where HTA is linked to broader health system reforms, including the generalization of Mandatory Health Insurance and the pursuit of Universal Health Coverage. The paper concludes that institutionalizing HTA represents a major opportunity to improve healthcare quality, efficiency, equity, and governance.
Ahid et al. (Thu,) studied this question.